Pharming presents leniolisib pediatric APDS data at Clinical Immunology Society meeting
PUBT · 10h ago
Share
Listen to the news
- Pharming Group to present leniolisib data at Clinical Immunology Society 2026 Annual Meeting, scheduled May 6-9 in New Orleans.
- Program includes interim pediatric long-term extension results in APDS, plus clinical experience from expanded-access use in CVID and CVID-like disorders.
- Poster sessions listed for May 7-8, including pediatric APDS symptom reporting analyses and a phase 2 study design update in primary immunodeficiencies with enhanced PI3K pathway signaling.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070105PRIMZONEFULLFEED1001180429) on May 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved